Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $287.50 short put and a strike $282.50 long put offers a potential 21.07% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $287.50 by expiration. The full premium credit of $0.87 would be kept by the premium seller. The risk of $4.13 would be incurred if the stock dropped below the $282.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 68.58 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Boehringer's operating income edges up on Jardiance, animal health
Tue, 05 Apr 2022 08:00:00 +0000
Germany's unlisted Boehringer Ingelheim said operating income rose 1.8% in 2021, driven by more prescriptions of diabetes drug Jardiance and demand for its veterinary drugs as people purchased pets during the pandemic. Family-owned Boehringer said in a statement on Tuesday that full-year operating income came in at 4.7 billion euros ($5.16 billion), up from 4.6 billion a year earlier. The diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and also for the treatment of heart failure.
10 Biotech Stocks to Buy According to Billionaire David E. Shaw
Sat, 02 Apr 2022 22:43:57 +0000
In this piece, we will take a look at ten biotechnology stocks to buy according to billionaire DE Shaw. If you want to skip the details about the hedge fund manager and his investment philosophy, as well as skip the top five stocks on this list, then take a look at 5 Biotech Stocks to […]
Exxon Mobil, Google Lead Five Stocks Near Buy Points For Resilient Portfolio
Sat, 02 Apr 2022 12:00:43 +0000
Exxon Mobil and Google are among five stocks near buy points. A diverse portfolio can be more resilient amid market shifts.
4 Stocks Reporting Earnings the Week of April 4
Fri, 01 Apr 2022 22:56:45 +0000
The current earnings season officially comes to an end next week with prints from a final few well-known companies. Beginning the week of April 11, earnings for the first quarter of this year will kick-off with financial results from the biggest U.S. banks and financial institutions. Before then, we’ll get fourth quarter 2021 earnings reports from a classic retailer, a leading pharmaceutical company, and Canada’s biggest cannabis producer, among others. According to data compiled by FactSet, the
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
Fri, 01 Apr 2022 10:45:00 +0000
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Retevmo (marketed as Retsevmo® outside of the U.S.) is a selective and potent RET kinase inhibitor that is approved in multiple countries including the United States for treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive NSCLC, a
Also on Market Tamer…
Follow Us on Facebook